Supplementary Figure S3 from Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma

Christian Schmithals, Verena Köberle, Hüdayi Korkusuz,Thomas Pleli,Bianca Kakoschky, Eduardo Alonso Augusto,Ahmed Atef Ibrahim,Jose M. Arencibia,Vida Vafaizadeh,Bernd Groner, Horst-Werner Korf,Bernd Kronenberger,Stefan Zeuzem,Thomas J. Vogl,Oliver Waidmann,Albrecht Piiper

crossref（2023）

引用 0|浏览0

暂无评分

摘要

Supplementary Figure S3: Body weight of HepG2 (A) and Huh-7 (B) xenograft-bearing mice treated with iRGD, control (Ctl.) peptide, PBS and sorafenib (Sora).

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要